In this video, Donald Leggatt, Head of Investor Relations at London South East, interviews Alastair Smith, Chief Executive Officer at Avacta Group. The AIM-listed company, which recently raised £11.6 million, has developed Affimer® technology, an alternative to antibodies, for use in research, diagnostics, and therapeutics. In this interview, Alastair Smith provides an operational update and outlines Avacta's plans for future development.
This interview was filmed and produced by the financial website group London South East, www.lse.co.uk.
Learn more: In July 2018, Avacta's CEO spoke to LSX about Affimer® technology's market potential, licensing and partnering opportunities, and the company’s strategic objectives. Read the interview here.
Feature image © REDPIXEL – stock.adobe.com